FDA authorizes modular PMA pathway for FemBloc, a potential speed boost to approval
FDA has authorized the modular PMA pathway for FemBloc, a non-surgical permanent birth control technology. This regulatory framework could streamline the PMA process and shorten the path to potential approval, reducing development risk and potentially boosting investor confidence in FEMY as FemBloc moves toward market readiness.
View signal analysis